London
· Delayed Price · Currency is GBP · Price in USD Viridian Therapeutics Statistics
Total Valuation
LON:0K1R has a market cap or net worth of GBP 1.02 billion. The enterprise value is 591.48 million.
| Market Cap | 1.02B |
| Enterprise Value | 591.48M |
Important Dates
The next estimated earnings date is Thursday, February 27, 2025.
| Earnings Date | Feb 27, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +42.07% |
| Shares Change (QoQ) | +4.02% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 74.63M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | 2.63 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -3.08 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -4.02 |
Financial Position
The company has a current ratio of 18.55, with a Debt / Equity ratio of 0.03.
| Current Ratio | 18.55 |
| Quick Ratio | 18.21 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.12 |
| Interest Coverage | -103.04 |
Financial Efficiency
Return on equity (ROE) is -51.88% and return on invested capital (ROIC) is -34.14%.
| Return on Equity (ROE) | -51.88% |
| Return on Assets (ROA) | -32.14% |
| Return on Invested Capital (ROIC) | -34.14% |
| Return on Capital Employed (ROCE) | -38.74% |
| Revenue Per Employee | 2,397 |
| Profits Per Employee | -2.04M |
| Employee Count | 94 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -10.36% in the last 52 weeks. The beta is 1.35, so LON:0K1R's price volatility has been higher than the market average.
| Beta (5Y) | 1.35 |
| 52-Week Price Change | -10.36% |
| 50-Day Moving Average | 18.73 |
| 200-Day Moving Average | 17.82 |
| Relative Strength Index (RSI) | 39.62 |
| Average Volume (20 Days) | 724 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 8.22 |
Income Statement
In the last 12 months, LON:0K1R had revenue of GBP 225,322 and -191.81 million in losses. Loss per share was -3.18.
| Revenue | 225,322 |
| Gross Profit | -118.98M |
| Operating Income | -211.18M |
| Pretax Income | -191.81M |
| Net Income | -191.81M |
| EBITDA | -210.75M |
| EBIT | -211.18M |
| Loss Per Share | -3.18 |
Balance Sheet
The company has 561.99 million in cash and 17.36 million in debt, giving a net cash position of 544.63 million.
| Cash & Cash Equivalents | 561.99M |
| Total Debt | 17.36M |
| Net Cash | 544.63M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 527.86M |
| Book Value Per Share | 4.89 |
| Working Capital | 541.66M |
Cash Flow
In the last 12 months, operating cash flow was -146.97 million and capital expenditures -332,015, giving a free cash flow of -147.30 million.
| Operating Cash Flow | -146.97M |
| Capital Expenditures | -332,015 |
| Free Cash Flow | -147.30M |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | -93,722.27% |
| Pretax Margin | -85,127.23% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
LON:0K1R does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -42.07% |
| Shareholder Yield | -42.07% |
| Earnings Yield | -18.81% |
| FCF Yield | -14.45% |
Stock Splits
The last stock split was on November 13, 2020. It was a reverse split with a ratio of 0.0666666667.
| Last Split Date | Nov 13, 2020 |
| Split Type | Reverse |
| Split Ratio | 0.0666666667 |
Scores
LON:0K1R has an Altman Z-Score of 7.36.
| Altman Z-Score | 7.36 |
| Piotroski F-Score | n/a |